𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Triggering of TNFRSF25 promotes CD8+ T-cell responses and anti-tumor immunity

✍ Scribed by Tomasz J. Slebioda; Tania F. Rowley; John R. Ferdinand; Jane E. Willoughby; Sarah L. Buchan; Vadim Y. Taraban; Aymen Al-Shamkhani

Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
295 KB
Volume
41
Category
Article
ISSN
0014-2980

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

TNFRSF25 is a member of the TNF receptor superfamily (TNFRSF) that binds to the TNF‐like protein TL1A. Although recent studies have demonstrated a role for TNFRSF25 in regulating CD4^+^ T‐cell responses, it remains to be determined if TNFRSF25 functions as a costimulatory receptor for CD8^+^ T cells. Here, we demonstrate that ectopic expression of TL1A on mouse plasmacytomas promotes elimination of tumor cells in a CD8^+^ T‐cell‐dependent manner and renders mice immune to a subsequent challenge with tumor cells. To gain further insight into the role of TNFRSF25 in CD8^+^ T‐cell responses, we analyzed the effect of TNFRSF25 triggering on OT‐I TCR transgenic T cells. We demonstrate that TNFRSF25 triggering in vivo with soluble TL1A promotes the proliferation and accumulation of antigen‐specific CD8^+^ T cells as well as their differentiation into CTLs. Furthermore, we show that TNFRSF25 also functions as a costimulatory receptor for memory CD8^+^ T cells. Thus, TNFRSF25 triggering enhances the secondary expansion of endogenous antigen‐specific memory CD8^+^ T cells. Our data suggest that TNFRSF25 agonists, such as soluble TL1A, could potentially be used to enhance the immunogenicity of vaccines that aim to elicit human anti‐tumor CD8^+^ T cells.

📜 SIMILAR VOLUMES

Paradoxical enhancement of CD8 T cell-de
Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine
✍ Dev Karan; Arthur M. Krieg; David M. Lubaroff 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 371 KB 👁 1 views

## Abstract Generation of antigen‐specific CD8+ T cell responses is considered optimal for an effective immunotherapy against cancer. In this study, we provide a proof of principle that __in vitro__ observed diminished CD8+ T cell response provided a strong __in vivo__ tumor protection. Immunizatio

Visualizing the course of antigen-specif
Visualizing the course of antigen-specific CD8 and CD4 T cell responses to a growing tumor
✍ Ludger Klein; Lydie Trautman; Stelios Psarras; Silke Schnell; Anja Siermann; Rol 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 335 KB 👁 1 views

## Abstract Spontaneous tumors frequently express antigens that can be recognized by the immune system but nevertheless manage to evade immune surveillance. To better understand the mechanism of evasion, we followed CD8 and CD4 T cells reacting against a subcutaneously growing tumor, modified to ex

Immunization with tumor-derived ER chape
Immunization with tumor-derived ER chaperone grp170 elicits tumor-specific CD8+ T-cell responses and reduces pulmonary metastatic disease
✍ Xiang-Yang Wang; Latif Kazim; Elizabeth A. Repasky; John R. Subjeck 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 French ⚖ 142 KB

## Abstract Glucose‐regulated protein (grp) 170 is a molecular chaperone localized in endoplasmic reticulum (ER), which has been demonstrated to interact with the peptides translocated by transporter associated with antigen presentation (TAP). In our study, we have evaluated the therapeutic efficac